Skip to main content

eCTD Portal

Paragraphs Page

The WHO Prequalification Unit (PQT) is introducing an electronic Common Technical Document (eCTD) submission facility through the ePQS Portal for the prequalification of medicines and vaccines.

The eCTD is an internationally harmonized electronic format for submitting regulatory information and applications to regulatory authorities. It is based on the Common Technical Document (CTD) developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Further information is available on the ICH website.

The introduction of eCTD is intended to simplify document lifecycle management for both applicants and PQT, while enhancing the efficiency, consistency, and transparency of the assessment process.

Applications in eCTD format must be submitted through the ePQS Portal.

To support applicants in preparing compliant eCTD dossiers, PQT provides a range of guidance documents and technical resources, accessible through the links below. Information on the practical steps for submission is available on the ePQS Portal webpage.

The Transition Timeline to eCTD

The transition to mandatory eCTD submissions will be implemented in phases. PQT is currently in Phase 1. Phase 2 will commence on 30 September 2027.

PhaseAPIMF/API-PQ Products | FPP Products | FVP Products

Phase 1

Until September 29, 2027

Companies may voluntarily submit applications for new products in eCTD format.

Companies may voluntarily convert existing prequalified Product dossiers to eCTD.

Phase 2

From 30 September 2027

New product applications should be submitted in eCTD format.

Companies are encouraged to convert existing prequalified product dossiers and APIMFs to eCTD before the start of phase 3.

FPP products that are requalified during this phase will be asked to convert their dossiers to eCTD.

Phase 3

From 1 October 2029

All applications should be submitted in eCTD format.

All legacy product and APIMF dossiers must have been converted to eCTD format.

Dossier Conversion Guidance

Applicants should note the following principles regarding dossier conversion:

  • Applications currently under assessment in a non-eCTD format should remain in that format until the assessment has been completed. Conversion should occur thereafter in accordance with the transition timeline above.
  • Change applications in eCTD format cannot be submitted for products that are maintained in a non-eCTD format. The product dossier must first be converted to eCTD.
  • Once a product dossier has been converted to eCTD format, all subsequent submissions for that product must be provided in eCTD format.
  • Conversion of a legacy product dossier to eCTD can be initiated by submitting a Post-PQ change application under the subtype eCTD Baseline.

Validation of eCTD Submissions

Before submitting an eCTD application, WHO strongly recommends the use of an eCTD validation tool to verify compliance with applicable technical and regulatory requirements.

Applicants should ensure that the validation software used is current and regularly updated. Detailed validation reports can help identify and resolve issues before submission, thereby facilitating successful acceptance and review of the dossier.

Links

Webinars

Documents

NameCurrent VersionLegacy Version
eCTD - eCTD Submissions via the ePQS PortalV1.1V1.0
eCTD - WHO eCTD guidance for IndustryV1.0 
eCTD - FAQ WHO PQT04 June 202609 February 2026
eCTD - WHOPQT eCTD M1 Specification (Files-Elements-Folders)V1.01V1.0
eCTD - PQT Validation CriteriaV1.2V1.11
eCTD - ePQS Related Product and Application type matrix18 October 202430 August 2024
eCTD - Initial application documents18 October 202421 March 2024
eCTD - WHO PQT eCTD checksumsV2.0V1.0
eCTD - WHO PQT Technical Files10 May 2023 
eCTD - WHO PQT Valid Values XML28 October 202431 August 2023